


BenBedPhar Training School

NRF2 in Noncommunicable Diseases: from Bench to Bedside

PROGRAM AND ABSTRACTS

**Smolenice Castle, Slovakia
June 26—30, 2023**



cost

EUROPEAN COOPERATION
IN SCIENCE & TECHNOLOGY



**MINISTRY
OF EDUCATION, SCIENCE,
RESEARCH AND SPORT
OF THE SLOVAK REPUBLIC**





WELCOME

BenBedPhar Training School 2023

NRF2 in noncommunicable diseases: from bench to bedside


Dear BenBedPhar colleagues,

One of the most relevant COST tools is the implementation of training schools. Three training schools will be organized by BenBedPhar as part of our "capacity building objectives". The end goal is to promote a timely scientific community of NRF2 basic, pharmacological, and clinical researchers and entrepreneurs and to develop a "sense of belonging" to the EU scientific community. Our first training school is possible thanks to the positive and enthusiastic temper of Dr. Iveta Bernatova and the local organizers in Slovakia. They will make this training school a very successful vehicle for multidisciplinary training and international interaction of trainers and trainees.

Antonio Cuadrado

Chair of COST Action CA20121, BenBedPhar

 **cost**
EUROPEAN COOPERATION
IN SCIENCE & TECHNOLOGY





RTF
2019 27
731

VENUE

BenBedPhar Training School 2023

NRF2 in noncommunicable diseases: from bench to bedside



Smolenice Castle

Congress Centre of the Slovak Academy of Sciences, Zamocka 18, Smolenice, Slovakia



Information

kcsmolenice.sav.sk/en/





RTF
aria 2.1

CONTENTS

BenBedPhar Training School 2023

NRF2 in noncommunicable diseases: from bench to bedside

Welcome from CA20121 Chair.....	2
Welcome from local organizers.....	3
Local organizers.....	4
Venue.....	5
Contents.....	6
Program overview.....	8
Detailed program on June 26, 2023.....	9
Detailed program on June 27, 2023.....	9
Detailed program on June 28, 2023.....	10
Detailed program on June 29, 2023.....	11
Detailed program on June 30, 2023.....	11
Posters session I.....	13
Posters session II.....	14
Trainers' lectures.....	15
Antonio Cuadrado.....	16
Gina Manda.....	19
Albena T. Dinkova-Kostova.....	21
Anna Grochot-Przeczek.....	23
Manuela G. Lopez.....	24
Ioannis Trougakos.....	26
Iveta Bernatova.....	28
Practical presentations.....	29
Trainees' abstracts	31
Ivana Kuntic.....	32
Eduardo Cazalla Ibanez.....	33
Shara Natalia Sosa Cabrera	34
Lucia Viqueira Diaz-Alejo.....	35
Yang Luo.....	36




CONTENTS

BenBedPhar Training School 2023

NRF2 in noncommunicable diseases: from bench to bedside

Ivan Lucic.....	37
Francesca Prestia.....	38
Arif Kamil Salihoglu.....	39
Maria Jose Caballero Herrero.....	40
Georgios Psarias.....	41
Margarida Pedro.....	42
Miroslav Novak.....	43
Viktorija Maksimova.....	44
Jose Jimenez-Villegas.....	45
Fatma Yapıcı.....	46
Andrea Micurova.....	47
Marina Oskomic.....	48
Patricia Pavelkova.....	49
Thomas Dixon.....	50
Lucrezia Romana Rolfi.....	51
Valentina Sophia Rumanova	52
Iza Oblak.....	53
Adriana Martiskova.....	54
Daniel Carnicero-Senabre.....	55
Hatice Esenkaya.....	56
Mercedes Vallejo Mudarra.....	57
Michal Kluknavsky.....	58
Livia Gajdosova.....	59
Louisa Watt.....	60
Acknowledgements.....	64



Viktorija Maksimova

Affiliation: Department of applied pharmacy, Faculty of Medical Sciences, Goce Delcev University, Shtip, North Macedonia

Position: Associate Professor

Email: viktorija.maksimova@ugd.edu.mk



Viktorija Maksimova is an associate professor in pharmaceutical botany and pharmacognosy at the Department of applied pharmacy, Faculty of Medical Sciences at the University of Goce Delcev in Shtip, North Macedonia. She is a Master of Pharmacy and defended her PhD thesis in the topic of Antioxidative and cytotoxic effect of capsicinoids, in 2016 at the same University. Currently, she's working on medicinal plants, and she is interested in researching small bioactive molecules as a novel superior antioxidant and cytotoxic agents among polyphenols and alkaloids. Recently she has become interested in studying plant bioactive molecules as NRF2 modulators.

Piperine as a natural derived NRF2 stimulator in prevention or therapy of ROS induced diseases

Background: Piperine is the major alkaloid represented in *Piper nigrum* (black pepper) showing different pharmacological properties that are still extensively studied. Piperine's ability to activate the protein expression levels of NRF-2 and HO-1 and inhibit the protein expression levels of Keap-1, is directly influencing the antioxidative capacity of the cells and ROS homeostasis.

Results: Activation of NRF2 by piperine has triggered an antioxidant response cell system (HO-1, GSH, CAT, SOD) scavenging ROS, and decreasing lipid peroxidation in colon cancer cells. These results indicate that piperine may be an effective molecule in prophylactic aims of colon carcinogenesis by targeting the NF- κ B/NRF-2/Keap-1/HO-1 pathway. The novel effects of piperine in attenuating the oxidative stress in lung epithelial cells were shown recently. Treatment with piperine enhanced the NRF2 expression and reversed changes induced by cigarette smoke extract. Increased NRF2 levels promoted anti-inflammatory effect in the same cells. Piperine has shown protective effects against A β -induced neuronal damage and oxidative stress, in the SH-SY5Y cell model. Activation of NRF2 pathway can also lead to inhibition of LPS-induced inflammatory response in microglial cells. In addition, a novel piperine derivative, HJ105, obtained through structure-based design and optimization was revealed in 2021, as a potent small molecule for treatment of Alzheimer disease. This structure promoted effective suppression of Keap1-NRF2 complex formation, and additional neuroprotective mechanisms of HJ105 underlying apoptotic cell death, oxidative stress response and neuro-inflammation.

Conclusions: Piperine and even more its derivatives are attracting increasing attention for their anti-apoptotic, anti-inflammatory, anti-antioxidant, cytoprotective and cognitive enhancing effects.